Table 6. Trials using SABR for early stage lung cancers.

Trial	Ref	Remarks	Outcome
Lagerwaard et al.; 2012	(172)	SABR (60 Gy in 3, 5 or 8 Fc depending on tumour size and location) in potentially operable patients	LC at 1 and 3 years were 98% and 93% respectively. Less than 3% risk of grade 3 toxicity. Median OS exceeded 5 years. 30-day post-procedure related mortality was 0%
Chan et al.; 2012	(173)	16 stage-1 NSCLC medically inoperable with a median age of 82 years	2-year LC, DFS and OS were 91%, 71% and 87% respectively
Haasbeek et al.; 2011	(174)	SABR (at 7.5 Gy × 8 Fc) for centrally located early NSCLC	Distant metastases and comorbidities were the predominant cause of death. 3-year LC and OS rates were 90.2% and 51.1 respectively
Fakiris et al.; 2009	(175)	Phase-II prospective trial involving 70 early staged NSCLC treated with SABR (60-66 Gy)	SABR results in high rates of local control in medically inoperable patients of early NSCLC. Cancer specific survival at 3 years was 81.7%
Timmerman et al.; 2010	(176)	Phase-II prospective trial of Early stage NSCLC who were medically inoperable treated with SABR (18 Gy × 3 Fc)	3-year DFS and OS were 48.3% and 55.8% respectively

LC, local contol; NSCLC, non small cell lung carcinoma; DFS, disease free survival; OS, overall survival; Fc, fraction; SABR, stereotactic ablative radiotherapy.